These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

542 related articles for article (PubMed ID: 30085394)

  • 21. Antibody-mediated rejection with and without donor-specific anti-human leucocyte antigen antibodies: performance of the peripheral blood 8-gene expression assay.
    Van Loon E; Lerut E; de Loor H; Kuypers D; Emonds MP; Anglicheau D; Gwinner W; Essig M; Marquet P; Naesens M
    Nephrol Dial Transplant; 2020 Aug; 35(8):1328-1337. PubMed ID: 32594133
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Late Antibody-Mediated Rejection in a Large Prospective Cross-Sectional Study of Kidney Allograft Recipients--Preliminary Results of the Screening Phase of the BORTEJECT Trial.
    Eskandary F; Bond G; Regele H; Kozakowski N; Kikić Z; Wahrmann M; Haslacher H; Oberbauer R; Ramassar V; Halloran P; Böhmig GA
    Clin Transpl; 2014; ():189-95. PubMed ID: 26281144
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identifying Subphenotypes of Antibody-Mediated Rejection in Kidney Transplants.
    Halloran PF; Merino Lopez M; Barreto Pereira A
    Am J Transplant; 2016 Mar; 16(3):908-20. PubMed ID: 26743766
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differences in pathologic features and graft outcomes in antibody-mediated rejection of renal allografts due to persistent/recurrent versus de novo donor-specific antibodies.
    Haas M; Mirocha J; Reinsmoen NL; Vo AA; Choi J; Kahwaji JM; Peng A; Villicana R; Jordan SC
    Kidney Int; 2017 Mar; 91(3):729-737. PubMed ID: 28104301
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Utility of protocol kidney biopsies for de novo donor-specific antibodies.
    Parajuli S; Reville PK; Ellis TM; Djamali A; Mandelbrot DA
    Am J Transplant; 2017 Dec; 17(12):3210-3218. PubMed ID: 28805293
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modeling graft loss in patients with donor-specific antibody at baseline using the Birmingham-Mayo (BirMay) predictor: Implications for clinical trials.
    Bentall A; Smith BH; Gonzales MM; Bonner K; Park WD; Cornell LD; Dean PG; Schinstock CA; Borrows R; Lefaucheur C; Loupy A; Stegall MD
    Am J Transplant; 2019 Aug; 19(8):2274-2283. PubMed ID: 30768833
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Donor-Recipient Matching Based on Predicted Indirectly Recognizable HLA Epitopes Independently Predicts the Incidence of De Novo Donor-Specific HLA Antibodies Following Renal Transplantation.
    Lachmann N; Niemann M; Reinke P; Budde K; Schmidt D; Halleck F; Pruß A; Schönemann C; Spierings E; Staeck O
    Am J Transplant; 2017 Dec; 17(12):3076-3086. PubMed ID: 28613392
    [TBL] [Abstract][Full Text] [Related]  

  • 28. De Novo Donor-Specific Human Leukocyte Antigen Antibody Screening in Kidney Transplant Recipients After the First Year Posttransplantation: A Medical Decision Analysis.
    Kiberd BA; Miller A; Martin S; Tennankore KK
    Am J Transplant; 2016 Nov; 16(11):3212-3219. PubMed ID: 27106124
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Coordinated Circulating T Follicular Helper and Activated B Cell Responses Underlie the Onset of Antibody-Mediated Rejection in Kidney Transplantation.
    Louis K; Macedo C; Bailly E; Lau L; Ramaswami B; Marrari M; Landsittel D; Chang A; Chandran U; Fadakar P; Yamada M; Chalasani G; Randhawa P; Zeevi A; Singh H; Lefaucheur C; Metes D
    J Am Soc Nephrol; 2020 Oct; 31(10):2457-2474. PubMed ID: 32723838
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Posttransplant peripheral blood donor-specific interferon-γ enzyme-linked immune spot assay differentiates risk of subclinical rejection and de novo donor-specific alloantibodies in kidney transplant recipients.
    Crespo E; Cravedi P; Martorell J; Luque S; Melilli E; Cruzado JM; Jarque M; Meneghini M; Manonelles A; Donadei C; Lloberas N; Gomà M; Grinyó JM; Heeger P; Bestard O
    Kidney Int; 2017 Jul; 92(1):201-213. PubMed ID: 28274484
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of donor-specific antibody with low mean fluorescence intensity on allograft outcomes in kidney transplant.
    Kitpermkiat R; Kantachuvesiri S; Thotsiri S; Thammanichanond D; Rostaing L; Wiwattanathum P
    Transpl Immunol; 2024 Jun; 84():102054. PubMed ID: 38750972
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Deceased donor kidney transplantation across donor-specific antibody barriers: predictors of antibody-mediated rejection.
    Schwaiger E; Eskandary F; Kozakowski N; Bond G; Kikić Ž; Yoo D; Rasoul-Rockenschaub S; Oberbauer R; Böhmig GA
    Nephrol Dial Transplant; 2016 Aug; 31(8):1342-51. PubMed ID: 27190362
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characteristics of Circulating Donor Human Leukocyte Antigen-specific Immunoglobulin G Antibodies Predictive of Acute Antibody-mediated Rejection and Kidney Allograft Failure.
    Kannabhiran D; Lee J; Schwartz JE; Friedlander R; Aull M; Muthukumar T; Campbell S; Epstein D; Seshan SV; Kapur S; Sharma VK; Suthanthiran M; Dadhania D
    Transplantation; 2015 Jun; 99(6):1156-64. PubMed ID: 25629531
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Donor-Specific Antibody Is Associated with Increased Expression of Rejection Transcripts in Renal Transplant Biopsies Classified as No Rejection.
    Madill-Thomsen KS; Böhmig GA; Bromberg J; Einecke G; Eskandary F; Gupta G; Hidalgo LG; Myslak M; Viklicky O; Perkowska-Ptasinska A; Halloran PF;
    J Am Soc Nephrol; 2021 Nov; 32(11):2743-2758. PubMed ID: 34253587
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical Significance of Pretransplant Donor-Specific Antibodies in the Setting of Negative Cell-Based Flow Cytometry Crossmatching in Kidney Transplant Recipients.
    Adebiyi OO; Gralla J; Klem P; Freed B; Davis S; Wiseman AC; Cooper JE
    Am J Transplant; 2016 Dec; 16(12):3458-3467. PubMed ID: 27140940
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lower tacrolimus exposure and time in therapeutic range increase the risk of de novo donor-specific antibodies in the first year of kidney transplantation.
    Davis S; Gralla J; Klem P; Tong S; Wedermyer G; Freed B; Wiseman A; Cooper JE
    Am J Transplant; 2018 Apr; 18(4):907-915. PubMed ID: 28925597
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Isolated v-lesion in kidney transplant recipients: Characteristics, association with DSA, and histological follow-up.
    Rabant M; Boullenger F; Gnemmi V; Pellé G; Glowacki F; Hertig A; Brocheriou I; Suberbielle C; Taupin JL; Anglicheau D; Legendre C; Duong Van Huyen JP; Buob D
    Am J Transplant; 2018 Apr; 18(4):972-981. PubMed ID: 29206350
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of Tocilizumab (Anti-Interleukin-6 Receptor Monoclonal) as a Potential Treatment for Chronic Antibody-Mediated Rejection and Transplant Glomerulopathy in HLA-Sensitized Renal Allograft Recipients.
    Choi J; Aubert O; Vo A; Loupy A; Haas M; Puliyanda D; Kim I; Louie S; Kang A; Peng A; Kahwaji J; Reinsmoen N; Toyoda M; Jordan SC
    Am J Transplant; 2017 Sep; 17(9):2381-2389. PubMed ID: 28199785
    [TBL] [Abstract][Full Text] [Related]  

  • 39. B-cell activating factor, a predictor of antibody mediated rejection in kidney transplantation recipients.
    Pongpirul W; Chancharoenthana W; Pongpirul K; Leelahavanichkul A; Kittikowit W; Jutivorakool K; Nonthasoot B; Avihingsanon Y; Eiam-Ong S; Praditpornsilpa K; Townamchai N
    Nephrology (Carlton); 2018 Feb; 23(2):169-174. PubMed ID: 27888573
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protocol Biopsies in Patients With Subclinical De Novo Donor-specific Antibodies After Kidney Transplantation: A Multicentric Study.
    Bertrand D; Gatault P; Jauréguy M; Garrouste C; Sayegh J; Bouvier N; Caillard S; Lanfranco L; Galinier A; Laurent C; Etienne I; Farce F; François A; Guerrot D
    Transplantation; 2020 Aug; 104(8):1726-1737. PubMed ID: 32732853
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.